Is Abiomed a Bad-News Buy Right Now?
2019 has been a rotten year for Abiomed's (NASDAQ: ABMD) investors. Shares of the temporary heart pump maker have fallen more than 40% since January in response to a slew of negative headlines. Meanwhile, Abiomed's revenue and net income have continued to grow. The combination has pulled the company's valuation down to the lowest level in years.
Is Abiomed a "bad news" buy, or are shares too risky to touch?
Source Fool.com